At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 70 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04324125N/ARecruitingUpdate OverdueUpdated 21mo ago · Completion was 18mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer
In Brief
An observational study for Non Small Cell Lung Cancer. Currently recruiting, targeting 70 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/ARecruitingOverdue
202120222023202420252026
Enrollment StartMar 2020
First PostedMar 2020
Primary CompletionDec 2024
Study CompletionMar 2025
TodayJul 2026
First PostedMar 27, 2020
Enrollment StartMar 24, 2020
Primary CompletionDec 24, 2024
Study CompletionMar 24, 2025
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 6.3 years ago